Shelley K. Ballentine
Janssen Pharmaceutica
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shelley K. Ballentine.
Bioorganic & Medicinal Chemistry Letters | 2012
Raul R. Calvo; Sanath K. Meegalla; Daniel J. Parks; William H. Parsons; Shelley K. Ballentine; Mary Lou Lubin; Craig Schneider; Raymond W. Colburn; Christopher M. Flores; Mark R. Player
Thermosensitive transient receptor potential melastatin 8 (TRPM8) antagonists are considered to be potential therapeutic agents for the treatment of cold hypersensitivity. The discovery of a new class of TRPM8 antagonists that shows in vivo efficacy in the rat chronic constriction injury (CCI)-induced model of neuropathic pain is described.
Bioorganic & Medicinal Chemistry Letters | 2012
Nalin L. Subasinghe; Ehab Khalil; Jeremy M. Travins; Farah Ali; Shelley K. Ballentine; Heather Rae Hufnagel; Wenxi Pan; Kristi A. Leonard; Roger F. Bone; Richard M. Soll; Carl S. Crysler; Nisha Ninan; Jennifer Kirkpatrick; Michael X. Kolpak; Karen DiLoreto; Stephen H. Eisennagel; Norman D. Huebert; Christopher J. Molloy; Bruce E. Tomczuk; Michael David Gaul
Complement C1s protease inhibitors have potential utility in the treatment of diseases associated with activation of the classical complement pathway such as humorally mediated graft rejection, ischemia-reperfusion injury (IRI), vascular leak syndrome, and acute respiratory distress syndrome (ARDS). The utility of biphenylsulfonyl-thiophene-carboxamidine small-molecule C1s inhibitors are limited by their poor in vivo pharmacokinetic properties. Pegylation of a potent analog has provided compounds with good potency and good in vivo pharmacokinetic properties.
Bioorganic & Medicinal Chemistry Letters | 2013
Carl R. Illig; Carl L. Manthey; Sanath K. Meegalla; Mark J. Wall; Jinsheng Chen; Kenneth J. Wilson; Renee L. Desjarlais; Shelley K. Ballentine; Carsten Schubert; Carl S. Crysler; Yanmin Chen; Christopher J. Molloy; Margery A. Chaikin; Robert R. Donatelli; Edward J. Yurkow; Zhao Zhou; Mark R. Player; Bruce E. Tomczuk
Structure-activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7 nM, FMS cell IC50 6.1 nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats.
Archive | 2007
Carl R. Illig; Shelley K. Ballentine; Jinsheng Chen; Renee L. Desjarlais; Sanath K. Meegalla; Mark J. Wall; Kenneth J. Wilson
Archive | 2005
Carl R. Illig; Shelley K. Ballentine; Jinsheng Chen; Sanath K. Meegalla; Jonathan Rudolph; Mark J. Wall; Kenneth J. Wilson; Renee L. Desjarlais; Carl L. Manthey; Christopher M. Flores; Christopher J. Molloy
Archive | 2006
Shelley K. Ballentine; Christian Andrew Baumann; Jingsheng Chen; Carl R. Illig; Saneth K. Meegalla; M. Jonathan Rudolph; Robert W. Tuman; Mark J. Wall; Kenneth J. Wilson; Dana L. Johnson
Archive | 2009
Mark R. Player; Daniel J. Parks; William H. Parsons; Sanath K. Meegalla; Carl R. Illig; Shelley K. Ballentine
Archive | 2007
Carl R. Illig; Shelley K. Ballentine; Jinsheng Chen; Sanath K. Meegalla; M. Jonathan Rudolph; Mark J. Wall; Kenneth J. Wilson; Renee L. Desjarlais; Carl M. Manthey; Christopher J. Molloy
Archive | 2006
Nalin L. Subasinghe; Shelley K. Ballentine; Jeremy M. Travins; Ehab Khalil; Farah Ali; Kristi A. Leonard; Joan M. Gushue; Michael P. Winters; Heather Rae Hufnagel; Maxwell D. Cummings
Archive | 2005
Carl R. Illig; Shelley K. Ballentine; Jinsheng Chen; Sanath K. Meegalla; Jonathan Rudolph; Mark J. Wall; Kenneth J. Wilson; Renee L. Desjarlais; Carl L. Manthey; Christopher M. Flores; Christopher J. Molloy